Zimmer J P, Lehr H A, Kornhuber M E, Breitig D, Montagnier L, Gietzen K
Blut. 1986 Dec;53(6):447-50. doi: 10.1007/BF00320308.
Previous reports have shown the capacity of diphenylhydantoin (DPH) to attach to the membranes of lymphatic cells as a hapten and thus exert an unspecific influence on their ability to express certain recognition molecules. This led us to the hypothesis, that DPH might as well serve to manipulate the t-helper-lymphocytes in a way that the mode of infection of these cells by the HIV might be blocked. In order to verify this hypothesis, we exposed normal control lymphocytes as well as lymphocytes from DPH-treated patients (3 X 100-150 mg DPH/day, Phenhydan, for a minimum of 10 days) to radioactively labeled HIV (125I). Remaining radioactivity was assessed using a gamma-counter and measured 64.000-92.000 counts/min (n = 24, mean 80.000) for the control lymphocytes, while remaining radioactivity for the DPH-treated lymphocytes ranged between 2000 and 7000 counts/min (n = 24, mean 4.000, p less than 0.001). These results and similar experiments obtained with FITC-labeled HIV led us to the conclusion that DPH inhibits HIV recognition of T-lymphocytes and therefore might be used in therapy and prophylaxis of AIDS.
先前的报告显示，二苯乙内酰脲（DPH）能够作为半抗原附着于淋巴细胞的细胞膜上，从而对其表达某些识别分子的能力产生非特异性影响。这使我们提出一个假设，即DPH或许也能够以某种方式操纵辅助性T淋巴细胞，从而阻断HIV对这些细胞的感染方式。为了验证这一假设，我们将正常对照淋巴细胞以及来自接受DPH治疗患者（每天3×100 - 150毫克DPH，苯妥英，至少10天）的淋巴细胞暴露于放射性标记的HIV（125I）中。使用γ计数器评估剩余放射性，对照淋巴细胞的测量值为64,000 - 92,000计数/分钟（n = 24，平均值80,000），而接受DPH治疗的淋巴细胞的剩余放射性则在2000至7000计数/分钟之间（n = 24，平均值4000，p小于0.001）。这些结果以及用异硫氰酸荧光素（FITC）标记的HIV所进行的类似实验使我们得出结论，DPH可抑制HIV对T淋巴细胞的识别，因此或许可用于艾滋病的治疗和预防。
